Jump to main content
Jump to site search


Integrated phenotypic screening and activity-based protein profiling to reveal potential therapy targets of pancreatic cancer

Author affiliations

Abstract

Pancreatic cancer has been defined as one of the most complex and challenging cancers to treat, but very few valid therapeutic targets have been identified to date. To address this issue, a 61-compound library was readily created by Ugi reaction followed by phenotypic screening, leading to the discovery of two most potent inhibitors, P21 and P26, which significantly impair BxPC-3 pancreatic cancer cell survival. A series of interacting protein hits, such as GSTO1, FAM213A, RAB6A/6B/39A and USMG5, were subsequently identified by quantitative chemoproteomics studies. The main cellular target, GSTO1, was further validated as a novel pancreatic cancer therapeutic target.

Graphical abstract: Integrated phenotypic screening and activity-based protein profiling to reveal potential therapy targets of pancreatic cancer

Back to tab navigation

Supplementary files

Publication details

The article was received on 02 Nov 2018, accepted on 10 Jan 2019 and first published on 10 Jan 2019


Article type: Communication
DOI: 10.1039/C8CC08753A
Citation: Chem. Commun., 2019, Advance Article
  •   Request permissions

    Integrated phenotypic screening and activity-based protein profiling to reveal potential therapy targets of pancreatic cancer

    W. Liu, Z. Zhang, Z. Zhang, P. Hao, K. Ding and Z. Li, Chem. Commun., 2019, Advance Article , DOI: 10.1039/C8CC08753A

Search articles by author

Spotlight

Advertisements